Mastracci, Luca
Fontana, Vincenzo
Queirolo, Paola
Carosio, Roberta
Grillo, Federica
Morabito, Anna
Banelli, Barbara
Tanda, Enrica
Boutros, Andrea
Dozin, Beatrice
Gualco, Marina
Salvi, Sandra
Romani, Massimo
Spagnolo, Francesco
Poggi, Alessandro
Pistillo, Maria Pia http://orcid.org/0000-0002-1154-4121
Funding for this research was provided by:
Italian Ministry of Health (5x1000 2014 and 2015)
Italian Ministry of Health (5x1000 2014 and 2015)
Italian Ministry of Health (5x100 2014 and 2015)
Italian Ministry of Health (project Code RF-2016-02362288)
Article History
Received: 5 August 2019
Accepted: 18 January 2020
First Online: 5 February 2020
Compliance with ethical standards
:
: Paola Queirolo served on the Advisory Boards of Roche, Novartis, Bristol-Myers Squibb, Merck Sharp and Dohme, Sanofi, and Pierre-Fabre. All other authors have declared no conflict of interest.
: The study was approved by the local Ethics Committee (CE) of the Liguria Region (CE-IST OMA07.024 amended on January 2nd 2011). All procedures performed in the study were in accordance with the Helsinki Declaration
: All patients signed an informed consent before enrollment in the study. In the leaflet of the consent, it was clearly explained that the patient would agree that part of the tumor tissue excised would be used for the immunological assessment foreseen in the study.